Literature DB >> 29667281

Estimated number of off-target candidate sites for antisense oligonucleotides in human mRNA sequences.

Tokuyuki Yoshida1,2, Yuki Naito3,4, Kiyomi Sasaki1,2, Eriko Uchida1, Yoji Sato2,5, Mikihiko Naito1, Toru Kawanishi6, Satoshi Obika2, Takao Inoue1,2.   

Abstract

Antisense oligonucleotide (ASO) therapeutics are single-stranded oligonucleotides which bind to RNA through sequence-specific Watson-Crick base pairings. A unique mechanism of toxicity for ASOs is hybridization-dependent off-target effects that can potentially occur due to the binding of ASOs to complementary regions of unintended RNAs. To reduce the off-target effects of ASOs, it would be useful to know the approximate number of complementary regions of ASOs, or off-target candidate sites of ASOs, of a given oligonucleotide length and complementarity with their target RNAs. However, the theoretical number of complementary regions with mismatches has not been reported to date. In this study, we estimated the general number of complementary regions of ASOs with mismatches in human mRNA sequences by mathematical calculation and in silico analysis using several thousand hypothetical ASOs. By comparing the theoretical number of complementary regions estimated by mathematical calculation to the actual number obtained by in silico analysis, we found that the number of complementary regions of ASOs could be broadly estimated by the theoretical number calculated mathematically. Our analysis showed that the number of complementary regions increases dramatically as the number of tolerated mismatches increases, highlighting the need for expression analysis of such genes to assess the safety of ASOs.
© 2018 The Authors. Genes to Cells published by Molecular Biology Society of Japan and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  RNA; antisense oligonucleotides; hybridization; off-target

Mesh:

Substances:

Year:  2018        PMID: 29667281     DOI: 10.1111/gtc.12587

Source DB:  PubMed          Journal:  Genes Cells        ISSN: 1356-9597            Impact factor:   1.891


  10 in total

Review 1.  Therapeutic approaches to Huntington disease: from the bench to the clinic.

Authors:  Nicholas S Caron; E Ray Dorsey; Michael R Hayden
Journal:  Nat Rev Drug Discov       Date:  2018-09-21       Impact factor: 84.694

2.  Silencing of MYH7 ameliorates disease phenotypes in human iPSC-cardiomyocytes.

Authors:  Alexandra Dainis; Kathia Zaleta-Rivera; Alexandre Ribeiro; Andrew Chia Hao Chang; Ching Shang; Feng Lan; Paul W Burridge; W Robert Liu; Joseph C Wu; Alex Chia Yu Chang; Beth L Pruitt; Matthew Wheeler; Euan Ashley
Journal:  Physiol Genomics       Date:  2020-06-22       Impact factor: 3.107

3.  DUX4 Transcript Knockdown with Antisense 2'-O-Methoxyethyl Gapmers for the Treatment of Facioscapulohumeral Muscular Dystrophy.

Authors:  Kenji Rowel Q Lim; Adam Bittel; Rika Maruyama; Yusuke Echigoya; Quynh Nguyen; Yiqing Huang; Kasia Dzierlega; Aiping Zhang; Yi-Wen Chen; Toshifumi Yokota
Journal:  Mol Ther       Date:  2020-10-15       Impact factor: 11.454

4.  A U1i RNA that Enhances HIV-1 RNA Splicing with an Elongated Recognition Domain Is an Optimal Candidate for Combination HIV-1 Gene Therapy.

Authors:  Olivier Del Corpo; Ryan P Goguen; Camille M G Malard; Aïcha Daher; Susan Colby-Germinario; Robert J Scarborough; Anne Gatignol
Journal:  Mol Ther Nucleic Acids       Date:  2019-10-18       Impact factor: 8.886

5.  Evaluation of off-target effects of gapmer antisense oligonucleotides using human cells.

Authors:  Tokuyuki Yoshida; Yuki Naito; Hidenori Yasuhara; Kiyomi Sasaki; Hideya Kawaji; Jun Kawai; Mikihiko Naito; Haruhiro Okuda; Satoshi Obika; Takao Inoue
Journal:  Genes Cells       Date:  2019-11-12       Impact factor: 1.891

Review 6.  Progress in the Use of Antisense Oligonucleotides for Vaccine Improvement.

Authors:  Alexander Batista-Duharte; Luis Sendra; Maria José Herrero; Damiana Téllez-Martínez; Iracilda Zeppone Carlos; Salvador Francisco Aliño
Journal:  Biomolecules       Date:  2020-02-17

7.  Response of human macrophages to gamma radiation is mediated via expression of endogenous retroviruses.

Authors:  Natallia Mikhalkevich; Ina P O'Carroll; Rok Tkavc; Kateryna Lund; Gauthaman Sukumar; Clifton L Dalgard; Kory R Johnson; Wenxue Li; Tongguang Wang; Avindra Nath; Sergey Iordanskiy
Journal:  PLoS Pathog       Date:  2021-02-08       Impact factor: 6.823

8.  Reduction of Off-Target Effects of Gapmer Antisense Oligonucleotides by Oligonucleotide Extension.

Authors:  Hidenori Yasuhara; Tokuyuki Yoshida; Kiyomi Sasaki; Satoshi Obika; Takao Inoue
Journal:  Mol Diagn Ther       Date:  2022-01-07       Impact factor: 4.074

9.  Identification of nucleobase chemical modifications that reduce the hepatotoxicity of gapmer antisense oligonucleotides.

Authors:  Tokuyuki Yoshida; Kunihiko Morihiro; Yuki Naito; Atsushi Mikami; Yuuya Kasahara; Takao Inoue; Satoshi Obika
Journal:  Nucleic Acids Res       Date:  2022-07-22       Impact factor: 19.160

10.  A structure-specific small molecule inhibits a miRNA-200 family member precursor and reverses a type 2 diabetes phenotype.

Authors:  Hafeez S Haniff; Xiaohui Liu; Yuquan Tong; Samantha M Meyer; Laurent Knerr; Malin Lemurell; Daniel Abegg; Haruo Aikawa; Alexander Adibekian; Matthew D Disney
Journal:  Cell Chem Biol       Date:  2021-07-27       Impact factor: 8.116

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.